# AbbVie Inc. (ABBV) FY2024 Q3 P&L / Income Statement

- Company: AbbVie Inc. (ABBV)
- Period: 2024-07-01 to 2024-09-30
- Filing: Q3 FY2024 10-Q, filed 2024-11-04, accession number 0001551152-24-000040
- Page: https://plicit.ai/financials/abbv/fy2024-q3-income-statement
- Chart image: https://plicit.ai/charts/abbv-fy2024-q3-income-statement-sankey.png

## Chart details: Revenue by Key Product Portfolio by Product and Service

Income statement for 2024-07-01 through 2024-09-30. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenues**: 14,460,000,000 US dollars
- **Cost of products sold**: 4,212,000,000 US dollars
- **Gross profit (calculated)**: 10,248,000,000 US dollars
- **Operating expenses (calculated)**: 6,417,000,000 US dollars
- **Operating earnings**: 3,831,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 1,747,000,000 US dollars
- **Earnings before income tax expense**: 2,084,000,000 US dollars
- **Income tax expense**: 520,000,000 US dollars
- **Net earnings**: 1,564,000,000 US dollars
- **Aesthetics - Botox Cosmetic**: 671,000,000 US dollars
- **Aesthetics - Juvederm Collection**: 258,000,000 US dollars
- **Aesthetics - Other Aesthetics**: 310,000,000 US dollars
- **Eye Care - Alphagan/Combigan**: 62,000,000 US dollars
- **Eye Care - Lumigan/Ganfort**: 116,000,000 US dollars
- **Eye Care - Other Eye Care**: 207,000,000 US dollars
- **Eye Care - Ozurdex**: 119,000,000 US dollars
- **Eye Care - Restasis**: 21,000,000 US dollars
- **Hematologic Oncology - Epkinly**: 43,000,000 US dollars
- **Hematologic Oncology - Imbruvica**: 828,000,000 US dollars
- **Hematologic Oncology - Venclexta**: 677,000,000 US dollars
- **Immunology - Humira**: 2,227,000,000 US dollars
- **Immunology - Rinvoq**: 1,614,000,000 US dollars
- **Immunology - Skyrizi**: 3,205,000,000 US dollars
- **Neuroscience - Botox Therapeutic**: 848,000,000 US dollars
- **Neuroscience - Duodopa**: 111,000,000 US dollars
- **Neuroscience - Other Neuroscience**: 84,000,000 US dollars
- **Neuroscience - Qulipta**: 176,000,000 US dollars
- **Neuroscience - Ubrelvy**: 269,000,000 US dollars
- **Neuroscience - Vraylar**: 875,000,000 US dollars
- **Other Key Products - Linzess/Constella**: 234,000,000 US dollars
- **Other Key Products - Mavyret**: 302,000,000 US dollars
- **Undisclosed (calculated)**: 1,203,000,000 US dollars
- **Acquired IPR&D and milestones**: 82,000,000 US dollars
- **Research and development**: 2,130,000,000 US dollars
- **Selling, general and administrative**: 4,205,000,000 US dollars
- **Other operating income**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to AbbVie Inc.: $1.56 B; to noncontrolling interests: $3.00 M.